Waypoint Bio is using spatial biology and AI to validate in vivo CAR-T candidates for solid tumors before costly clinical trials.
Waypoint Bio is using spatial biology and AI to validate in vivo CAR-T candidates for solid tumors before costly clinical trials.
Le signal de fond est que l'IA quitte les démos pour entrer dans les budgets, les règles, la sécurité et l'allocation du capital.
Sources: BusinessWire; BioSpace; Precision Medicine Online; CocoLoop, CocoLoop.